RNAi Biotech Atalanta Unveils $97M to Reach the Clinic in Two Rare Neuro Diseases
The structure of Atalanta Therapeutics’ RNA interference drugs enables them to distribute broadly and deeply into brain tissue. Lead programs for Huntington’s disease and a rare inherited form epilepsy are on track to enter the clinic this year.